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Abstract
Background: This study focuses on the implementation of CYP2D6 genetic test
profiling and the challenges associated with using standard pharmacogenetics panels
in a diverse South Florida population.
Methods: A total of 413 participants were recruited to participate in this study
through Nicklaus Children's Hospital. Buccal swabs were collected and tested using
an extended CYP2D6 panel including 22 alleles. Phenotype, genotype, and allelic
frequencies were compared among different racial and ethnic groups.
Results: The majority of participants (75.0%) self‐identified as Hispanics. Four alleles, CYP2D6*4, *17, *41, and *2A, showed a statistically significant difference
between White Hispanics and Black Non‐Hispanics. Aggregate frequency of all alleles with decreased function varied between 2.8% and 50.0% in different racial and
ethnic groups. Additionally, rare allele combinations were observed in this South
Florida cohort.
Conclusions: The heterogeneity among Hispanic groups demonstrated in previous
literature and by this study reflects the complexity of ethnicity and suggests that a
more granular categorization is needed, one based on ancestry and migration history
rather than primary language. Overall, we have determined that there are statistically
significant differences in CYP2D6 allele frequencies in the distinct racial and ethnic
populations of South Florida, demonstrating a unique genetic makeup within South
Florida. However, overall, the frequencies of Poor Metabolizer, Normal Metabolizer,
Intermediate Metabolizer, and Ultrarapid Metabolizer did not differ between racial
and ethnic groups at a statistically significant level.
KEYWORDS
CYP2D6, ethnicity, Hispanic, intermediate metabolizers, normal metabolizers, pharmacogenetics, poor
metabolizers, race, ultrarapid metabolizers
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IN TRO D U C T ION

Cytochrome P450 2D6 (CYP2D6) is an enzyme metabolizing
approximately 25% of therapeutic drugs, including antidepressants, antipsychotics, analgesics, antitussives, beta‐adrenergic blocking agents, antiarrhythmics, and antiemetics
(NIH, 2017a). This drug‐metabolizing enzyme is encoded by
a highly polymorphic CYP2D6 gene with more than 100 variant alleles located on chromosome 22q13.1 (Daly et al., 1996;
NIH, 2017a) (OMIM #608902, NM_001195406). Each
CYP2D6 allele (or haplotype) is defined by a specific profile of single‐nucleotide polymorphisms (SNPs), insertions,
deletions, duplications, and multiplications (Crews, 2014).
As allelic variants influence protein expression and activity,
CYP2D6 polymorphisms impact the enzyme's functional capacity to metabolize therapeutic drugs. CYP2D6 alleles are
phenotypically defined by their expected influence on overall
CYP2D6 enzymatic activity, such as no function, decreased
function, normal function, increased function, unknown, and
uncertain function (Caudle, 2017). An individual's CYP2D6
diplotype, or their combination of maternal and paternal alleles, comprehensively determines CYP2D6 metabolic activity
as poor metabolizers (PMs), intermediate metabolizers (IMs),
normal metabolizers (NMs), or ultrarapid metabolizers (UMs)
(NIH, 2017a). An UM phenotype is a result of gene duplication or multiplication which occurs from inheriting more
than two copies of the fully functional CYP2D6 alleles (UM)
(Crews, 2014).
The efficacy and toxicity of a therapeutic drug metabolized by CYP2D6 can differ from person‐to‐person depending on an individual's CYP2D6 genotype and phenotype. One
example is codeine, an opioid analgesic indicated to relieve
mild to moderate pain through codeine metabolism and morphine activation by CYP2D6 enzymes (NIH, 2017b). Data
show that CYP2D6 PMs demonstrate significantly lower
morphine serum concentrations and analgesia in comparison
to NMs who receive identical doses of codeine (Eckhardt et
al., 1998). Meanwhile, CYP2D6 UMs exhibit an increased
conversion of codeine to morphine in comparison to NMs,
which can result in toxic concentrations of morphine and life‐
threatening adverse reactions (Ciszkowski, Madadi, Phillips,
Lauwers, & Koren, 2009; Dalén, Frengell, Dahl, & Sjöqvist,
1997; Gasche, 2004). For this reason, it is vital to understand CYP2D6 pharmacogenetics and how CYP2D6 polymorphisms influence a patient's favorable or adverse clinical
responses to drugs metabolized by CYP2D6 enzymes (NIH,
2016).
Based on the U.S. census estimates in 2016, 67.7% of
Miami‐Dade residents identified as Hispanic or Latino compared to 17.8% nationally (U.S. Census Bureau, 2016). Given
that the CYP2D6 allele, genotype, and phenotype frequencies may differ substantially among ethnic and racial groups,
pharmacogenetic testing may be used to personalize and
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improve treatment for diverse patient populations (NIH, 2017;
Owusu‐Obeng et al., 2014). Studies have demonstrated that
certain Hispanic groups have CYP2D6 alleles that are rare
in non‐Hispanic populations (Bernard, 2006; Casner, 2005;
Gaedigk, 2010; Luo, Gaedigk, Aloumanis, & Wan, 2005).
However, current pharmacogenetics research focuses primarily on White Non‐Hispanics (Claudio‐Campos, Duconge,
Cadilla, & Ruaño, 2015; Ortega & Meyers, 2014; Ramos,
Callier, & Rotimi, 2012), which may lead to a misrepresentation of allelic frequency estimates in highly diverse Hispanic
or Latino populations, such as those in South Florida.
The genotyping of CYP2D6 involves analysis of a select
number of known SNPs and genetic variants. However, the
number of screened variants is inconsistent across laboratories, ranging from 3 to 35 alleles (Flores‐Angulo, 2015;
Gaedigk, Bradford, Marcucci, & Leeder, 2002; Gaedigk et
al., 1999; Kohlrausch, 2009; Leathart et al., 1998; López,
Guerrero, Jung‐Cook, & Alonso, 2005). The inconsistencies
in results are due to laboratories differing in test design, including what alleles are interrogated and how the alleles are
identified. This leaves many alleles untested and undetected,
which may return false‐negative results (Bell, 2017; Gaedigk
et al., 1999).
Our study focused on the unique CYP2D6 genetic profile of the South Florida population. We examined the allele
and phenotype frequencies among different combinations of
races and ethnicities. Due to a lack of diversity in the currently available pharmacogenetics research and data, we
hypothesized that these differences would be statistically significant in the South Florida population.
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Ethical compliance

Western Institutional Review Board approved the study and
all participants and their caregivers provided consent/assent
when appropriate.
Patients of Nicklaus Children's Hospital were recruited to
participate in this study (N = 413). Most participants enrolled
at the end of their visit with the neurology, plastic surgery,
or hematology/oncology departments. Patients and family
members attending the hospital's Cancer Center Mini Relay
for Life were also introduced to the study and invited to participate. All patients had to be between the ages of 1–21 years
and reside in the South Florida area to be eligible for the
study.
Participants were asked to provide their race as either
White, Black, Asian, or Mixed, and categorized their ethnicity as Hispanic or Non‐Hispanic. There were 37 participants (8.9%) who refused to provide this information.
These patients were included in the analysis of total frequencies of phenotypes. Buccal swabs were collected
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for DNA extraction. All samples were genotyped at the
Genelex® Corporation (Genelex Corporation) using an
extended CYP2D6 (OMIM #608902, NM_001195406)
panel with enough sensitivity to capture over 93.0%–97.0%
of the low‐frequency PM phenotypes. Genelex® was selected based on several factors including clinical decision
support, turnaround time, breadth of the panel, and cost.
Twenty‐two alleles were included in the panel: CYP2D6
*1, *2, *2A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *14A,
*15, *17, *19, *20, *29, *35, *36, and *41.
All participants and their primary caregivers if requested
were mailed a copy of their individual phenotype/genotype
results. The patients were also offered a consultation with a
genetic counselor if they wanted a detailed explanation of the
study results.
Subsequently, genotype results were analyzed. Allelic frequencies were assessed for statistically significant differences
at a 95% confidence interval (CI) for proportions. CI was calculated as p ± 1.96 × SE, where SE = sqrt(p × (1 − p)/n); p is
the proportion of an allelic variant or a phenotype in a given
race and ethnicity group; n is the total number of patients
in the same group. If 95% CI did not overlap, the difference
was determined to be statistically significant. All statistical
analysis was performed in R. Of note, the interpretation of activity scores by Genelex® for PMs, IMs, NMs, and UMs differed from that of Clinical Pharmacogenetics Implementation
Consortium (CPIC) guidelines. CPIC definitions were used
in this study, namely, activity scores of 1.0–2.0 were considered NM.
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R E S U LTS

Of the 413 individuals enrolled in the study, 376 provided
information on their race and ethnicity, 75.0% identified as
Hispanic, and 19.0%, 2.0%, and 11.0% identified their race
as Black, Asian, and Mixed, respectively (Figure 1, Table 1).
Most of the participants (62.0%) were White Hispanic (WH)
followed by Black Non‐Hispanic (BNH) (16.0%). The most
common phenotype in this cohort was NM (90%), followed
by IM (4.0%) (Figure 2). The UM and PM phenotypes were
equally represented at 3.0%. Of the 22 CYP2D6 alleles examined, 14 were identified in the South Florida population:
CYP2D6*1, *2, *2A, *3, *4, *5, *6, *9, *10, *17, *29, *35,
*36, and *41. Eight alleles from the panel were not present:
CYP2D6*7, *8, *11, *12, *14A, *15, *19, and *20.
In total, 10 SNPs and 10 deletions/duplications were detected, showing variable allele frequencies among different
race/ethnic groups (Figure 3). There were significant differences in frequencies among participants depending on their
race and ethnicity for four alleles: CYP2D6*4, *17, *41, and
*2A (Figure 3). The occurrence of a no‐function allele *4,
was more prevalent in WH (14.7%) than in BNH (2.4%). As
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F I G U R E 1 Study Participants' Ethnicity and Race (N = 376
nonmissing values). 75% identified Hispanic as their ethnicity. Most of
the participants (62%) were White Hispanic (WH) followed by Black
Non‐Hispanic (BNH) (16%)

a result, PM genotype combinations were only detected in
individuals self‐identifying as White.
Aggregate frequency of all decreased function alleles
varied between 2.8% in White Non‐Hispanic participants
and 50.0% in Mixed Non‐Hispanics. BNH subjects when
compared to WH had a significantly higher frequency of
CYP2D6*17 (15.3% vs. 2.8%), while CYP2D6*41 showed
a significant difference in the opposite direction (0.8% vs.
7.5%). (Figure 3).
Furthermore, in our study, the normal function
CYP2D6*2A allele was significantly more frequent in the
WH population (17.5%) than in the BNH (6.5%).
Finally, a rare allele combination and a unique duplication
were observed in this South Florida cohort. Specifically, we
found a BNH individual with four copies of normal function
including CYP2D6*1, *2A, and two *2‐like alleles. Since no
deleterious mutations were detected, it is assumed that all four
alleles are active, and the phenotype would be expected to be
UM. In addition, there was one BNH (0.8%) and one WH
(0.2%) study participant with the rare tandem allele *36‐10.
Overall, we have determined that there are statistically
significant differences in CYP2D6 allele frequencies in
the distinct racial and ethnic populations of South Florida,
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TABLE 1
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CYP2D6 phenotype frequencies grouped by race and ethnicity

Frequency
Poor metabolizer
Intermediate metabolizer
Normal metabolizer
UltraRapid metabolizer
Total

White Non‐
Hispanic
1

White
Hispanic

Mixed
Non‐Hispanic

10

0

Mixed
Hispanic
0

Black
Non‐Hispanic
0

Black
Hispanic

Asian
Non‐Hispanic

0

0

0

9

0

0

3

0

0

17

203

5

38

56

11

9

0

10

0

1

3

0

0

18

232

5

39

62

11

9

Note: OMIM gene ID: 608902, NM_001195406.

F I G U R E 2 Phenotypes of 413 participants. OMIM gene ID:
608902, NM_001195406

demonstrating a unique genetic makeup within South Florida.
However, overall, frequencies of PM, NM, IM, and UM did
not differ between racial and ethnic groups at a statistically
significant level (Table 1). The power to detect allele frequency differences between WH and BNH in our study was
90%, but to detect differences between other less represented
racial and ethnic groups dropped below 70%.
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D IS C U SS ION

The distribution of phenotypes in this study was similar to
what was previously described in literature; 4.0% IM, 3.0%
PM, 3.0% UM, and 90.0% NM versus 2.8%, 1.9%, 4.6%, and
92.3%, respectively (Flores‐Angulo, 2015). However, the
distribution of allele frequencies significantly varied between
ethnic and racial groups. Namely, alleles CYP2D6*2A, *4,
*17, and *41 showed prominent differences among WH and
BNH.

The nonfunctional allele CYP2D6*4 was frequent in WH
(14.7%), but not in BNH (2.4%), aligning with other studies
on WH participants from Cuba, Nicaragua, and Venezuela
(Flores‐Angulo, 2015; Griman, 2012; Kohlrausch, 2009).
Furthermore, a meta‐analysis of allele frequency studies on
healthy Puerto Ricans determined that their *4 frequency was
similar to White Non‐Hispanics (Bernard, 2006). The *4 allelic frequencies of a Mexican‐American population revealed
a somewhat lower frequency of 10% (Luo et al., 2005).
Lastly, the *4 allele was less frequent in South Florida BNH
compared to other BNH populations described in the literature (2.4% vs. 5.4%–7.8%) (Bradford, Gaedigk, & Leeder,
1998; Cai, 2006; Gaedigk et al., 2002; Leathart et al., 1998;
US Census Bureau, 2010a; Wan et al., 2001).
Furthermore, BNHs in this study had a greater frequency of decreased function allele CYP2D6*17 (15.3%)
compared to WHs (2.8%). These findings also align with
reports from other studies on similar populations (Agúndez,
Ramirez, Hernandez, Llerena, & Benítez, 1997; Bradford
et al., 1998; Cai, 2006; Gaedigk et al., 2002; Isaza, Henao,
López, & Cacabelos, 2000; Kohlrausch, 2009; Leathart et
al., 1998; Llerena et al., 2012; Wan et al., 2001). However,
other in‐depth studies are demonstrating significant variation among Hispanics. Namely, one study compared the
presence of *17 between Cuban Mestizos, Nicaraguan
Mestizos, and White Cubans. The allele was most prevalent
in the Cuban Mestizos (10.2%). Meanwhile, none of the
Nicaraguan Mestizos had *17, but 2.7% of the White Cuban
population did (Llerena et al., 2012). Another study conducted in Costa Rica analyzed three different ethnic groups:
Mestizo, Amerindian, and Afro‐Caribbean, and demonstrated that a greater proportion of the Afro‐Caribbean
group (18.4%) had *17. The Mestizo and Amerindian populations also had *17 but to a lesser extent (1.8% and 2.2%
respectively) (Céspedes‐Garro, 2014).
Another allele with decreased function showing significant differences between South Florida's racial and ethnic
groups was CYP2D6*41. It was found in 7.5% of WH and
only 0.8% of BNH populations. In comparison, a Spanish
study reported a frequency of 3.8% in WH (Fernández‐
Santander, 2010) and a study on Mexican‐Americans found
a frequency of 9.5% (Luo et al., 2005). Furthermore, the
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CYP2D6*17

CYP2D6*1xN
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Race and Ethnicity

White Non-Hispanic
White Hispanic
Mixed Non-Hispanic
Mixed Hispanic
Black Non-Hispanic
Black Hispanic
Asian Non-Hispanic
White Non-Hispanic
White Hispanic
Mixed Non-Hispanic
Mixed Hispanic
Black Non-Hispanic
Black Hispanic
Asian Non-Hispanic
White Non-Hispanic
White Hispanic
Mixed Non-Hispanic
Mixed Hispanic
Black Non-Hispanic
Black Hispanic
Asian Non-Hispanic
White Non-Hispanic
White Hispanic
Mixed Non-Hispanic
Mixed Hispanic
Black Non-Hispanic
Black Hispanic
Asian Non-Hispanic

0 20 40 60

0 20 40 60

0 20 40 60

0 20 40 60

Percent with 95% Confidence Interval

F I G U R E 3 CYP2D6 allele frequencies grouped by race and ethnicity and enzyme activity categories with corresponding 95% CI. The
biggest difference in allele frequencies among the “poor metabolizers” was observed for the *4 allele, varying between 2.4% and 14.7% in Black
Non‐Hispanic and White Hispanic respectively. OMIM gene ID: 608902, NM_001195406

reported frequencies of *41 in BNH populations markedly
vary (1.8%–14.4%) (Cai, 2006; Gaedigk, 2005). Notably,
alleles *41 and *2A were not distinguished until recently.
Specifically, *2A involves a −1584C>G substitution while
*41 involves a 2988G>A polymorphism (Daly et al., 1996).
Therefore, before the 2988G>A SNP was characterized as a
unique marker identifying *41, the sole method of differentiating *41 from *2A was by testing for the absence of SNP
1584C>G (Kennedy, 2008). Because of their similarity, not
all prior studies tested for *41 and may have inadvertently
reported larger frequencies of *2A in the tested populations.
These issues have challenged the ability of researchers to
accurately report *2A frequencies until recently (Blake,
2007; Cai, 2006; Gaedigk et al., 1999; Gaedigk, 2005, 2008;
Griman, 2012; Kennedy, 2004, 2008).
This study is the first to identify a CYP2D6*36‐10 allele
in a WH participant. The tandem allele *36‐10 is prevalent
in Japanese populations (24.2%–26.7%), but rarely detected

among African‐Americans (0.4%), and not reported in
White populations (Hosono, 2009; Kiyotani, 2010; Soyama
et al., 2004; Soyama, 2006). There are insufficient data on
Hispanics or Latinos. The combination of a decreased function allele *10 with the no‐function allele *36 is thought to
contribute to a PM phenotype (Gaedigk, Bradford, Alander,
& Leeder, 2006; Kiyotani, 2010). Notably, *10 has conflicting data on several Puerto Rican populations. One study
stated that *10 was found less frequently than in Caucasian
populations, while another reported that Puerto Ricans have
a *10 frequency similar to Caucasians (Claudio‐Campos,
Orengo‐Mercado, et al., 2015).
Our research findings describe more accurate representations of CYP2D6*2, *2A, *17, and *41 allele frequencies in
South Florida WH and BNH populations, and also identify
a rare *36‐10 allele in a WH, as well a unique *2A duplication that has not been well‐described in Hispanic populations.
Finally, CYP2D6 test results revealed that the PM phenotype
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was only found in White individuals, which could be potentially explained by our low number of non‐White study participants. These results highlight the need for data on a larger
number of non‐White populations and ethnic minorities.
In general, the frequency data on CYP2D6 *4, *17, *41,
and *2A in diverse populations is limited. Therefore, there is
a need to better characterize the CYP2D6 genotype and phenotype variability in Hispanics and Latinos.
In addition to these frequent alleles, there may be others
that are unique to Hispanics and Latinos that were not included in the study panel. For example, there have been studies among Latin American, Central American, and Hispanic
countries that have provided insight into unique allelic variants. One such study involved Mexican Mestizos, Mexican
individuals with a mixed European and American Indian
background. They discovered a rare variant CYP2D6*82 at
a frequency of 2.1% (Kiyotani, 2010). The functionality of
CYP2D6*82 is currently unknown but the origin was suggested to be American Indian. Another study on a Mexican
Mestizo population identified the normally functioning allele *53 in 0.5% of the sample (Contreras, 2011). Studies
have also identified rare no‐function CYP2D6*31 and *40
in several Hispanic populations. For instance, the allele
*31, associated with PMs, was discovered in two Spaniards
and two Puerto Ricans (Gaedigk, 2010). Another genotyping study on a Puerto Rican cohort noted two individuals: one who had *31 and one with *40 (Gaedigk, 2010).
Approximately 2.1%, 3.7%, and 0.6% of the Hispanic residents of Miami‐Dade County reported themselves in the
2010 Census as Mexican, Puerto Rican, and Spanish, respectively (US Census Bureau, 2010b). Allele *31 was not
tested in this study, but it would be beneficial to include
it in future pharmacogenomic panels for the South Florida
population.
Although there were significant variations in allelic frequencies, no statistically significant differences in phenotype
frequency were observed among the South Florida cohort
evaluated in this study. This may be a result of an insufficient sample size of non‐Hispanic and non‐White cohorts
and future larger studies are needed to prove this hypothesis.
Past studies demonstrated that the frequency of CYP2D6 phenotypes among several Hispanic and Latino groups differs
from that of White non‐Hispanics across the Americas. A
retrospective review of phenotype frequencies among ethnic groups found that the frequency of PMs in non‐Hispanic
Whites from the Americas is 7.7%, while the frequency of
PMs among Colombians, Mexicans, Panamanians, and
Nicaraguans is markedly lower (6.6%, 3.2%, 2.2%–4.4%,
and 3.6% respectively) (Bernard, 2006). At the same time,
Mexican Mestizo had a frequency of PM phenotype similar
to the white Spanish population (10%) (López et al., 2005).
The review of UM phenotype frequencies also demonstrated ethnicity‐based differences. Hispanic UMs were less

SALYAKINA et al.

common when compared to white American UMs (1.7% vs.
4.3%) (Bernard, 2006). The heterogeneity among Hispanic
groups demonstrated in previous literature and by this study
reflects the complexity of ethnicity and suggests that a more
granular categorization is needed, one based on ancestry and
migration history rather than primary language. These results
prove once again that Hispanic ethnicity is not homogeneous,
but rather is a mix of various populations with very diverse
genetic backgrounds.
This study has a few limitations. WH and BNH were the
two largest population groups in the study. It is therefore not
surprising that the only statistically significant differences
found were between the two ethnic groups with the largest
sample sizes. It is possible that there are additional frequency
differences among other groups in this population, but this
study is underpowered to detect them. In addition, the race
and ethnicity used in this study were based on self‐reported
records by the study participants. These records may be imprecise and biased. Future studies should include design and
resources to allow for genetic confirmation or verification of
perceived ancestry.
Overall, our findings suggest that in predominantly
Hispanic or Latino populations, the assumption that allelic
and phenotype distributions are similar to less diverse populations may be inaccurate. As a result, pharmacogenetic
panels designed for less diverse populations may not be appropriate for Hispanic populations. If the subject of a test
has an allele that was not included in the panel, they risk improper classification of their CYP2D6 function. For example,
CYP2D6*31, *49, *50, *54, *55, *59, and *84 all translate
to decreased or no function, however, they were not tested
in this study and are not included in most commercial panels. It is currently not known whether these alleles are prevalent in Hispanics or Latinos. If a patient had any of these
alleles, they would be incorrectly classified as NM. That
could explain the markedly lower rates of PM previously reported in Hispanics (Bernard, 2006). Thus, pharmacogenetic
test results would be more useful and accurate if laboratories sequenced the entire CYP2D6 gene, rather than selected
polymorphisms. As a whole, sequencing would also provide
a better depiction of the allelic variation within underrepresented communities (Barron et al., 2016; Bernard, 2006;
Claudio‐Campos, Orengo‐Mercado, et al., 2015; Ortega &
Meyers, 2014). Importantly, minority groups are predicted to
become the majority by 2044, with a quarter being Hispanic
(Colby & Ortman, 2015). As the nation's diversity grows, it
is critical that the available pharmacogenetic tests reflect the
heterogeneity of the population.
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